文献速递呼吸衰竭与机械通气重症综合管理与镇静镇痛消化、代谢与肾脏急症

苏格兰COVID-19重症疫苗效力与delta变异株及第二剂接种后时间的关系(REACT-SCOT):病例对照研究

Vaccine efficacy against severe COVID-19 in relation to delta variant (B.1.617.2) and time since second dose in patients in Scotland (REACT-SCOT): a case-control study.
PubMed 文献 · Lancet Respir Med · 2022-02-25
一句话结论在苏格兰人群中,两剂ChAdOx1疫苗对COVID-19重症的效力随时间从第二剂接种后下降至20周时的69%,而mRNA疫苗在20周时仍维持93%;作者认为结果支持为重症高风险人群采取额外保护措施(包括但不限于加强针)。

该研究为REACT-SCOT匹配病例对照研究,纳入苏格兰2020年12月1日至2021年9月8日诊断的COVID-19病例,每例匹配10名按年龄(取整至年)、性别和初级保健诊所匹配且存活至病例就诊日的对照,主要结局为COVID-19重症(首次阳性检测后21天内进入重症监护、28天内死亡或COVID-19为根本原因的死亡)。共记录5645例重症病例和50096名对照;重症病例中4495例(80%)未接种疫苗,对照中36879例(74%)未接种;已接种的重症病例中389例接种mRNA疫苗、759例接种ChAdOx1疫苗。疫苗接种对COVID-19重症的效力在2021年5月下降,与alpha被delta变异株取代同时发生,但随后一个月内回升;在截至2021年7月29日的最新时间窗内,两剂ChAdOx1疫苗的效力为91%(95%CI 87-94),mRNA(辉瑞或莫德纳)疫苗为92%(88-95)。ChAdOx1疫苗对COVID-19重症的效力随第二剂接种后时间下降至20周时的69%(95%CI 52-80);mRNA疫苗的效力在第二剂接种后前10周下降,此后下降更慢,至20周时为93%(88-96)。作者认为结果令人安心,但ChAdOx1疫苗效力在第二剂后20周明显下降,mRNA疫苗20周后的效力及对更新变异株的效力尚待确定。

要点

  • 在截至2021年7月29日的最新时间窗内,两剂ChAdOx1疫苗对COVID-19重症的效力为91%(95%CI 87-94),mRNA(辉瑞或莫德纳)疫苗为92%(88-95)。
  • ChAdOx1疫苗对COVID-19重症的效力随第二剂接种后时间下降至20周时的69%(95%CI 52-80)。
  • mRNA疫苗对COVID-19重症的效力在第二剂接种后前10周下降,此后下降更慢,至20周时为93%(95%CI 88-96)。
  • 疫苗接种对COVID-19重症的效力在2021年5月下降,与alpha被delta变异株取代同时发生,但该下降在随后一个月内回升。
  • 作者认为结果支持为重症高风险人群采取额外保护措施,包括但不限于在传播率高或预计上升时接种加强针。

适用人群与场景

  • 苏格兰人群中2020年12月1日至2021年9月8日诊断的COVID-19病例;每例病例匹配10名按年龄(取整至年)、性别和初级保健诊所匹配且存活至病例就诊日的对照。
  • 主要结局评估为COVID-19重症:首次阳性检测后21天内进入重症监护、首次阳性检测后28天内死亡,或COVID-19被编码为根本原因的任何死亡。

诊断标准与关键阈值

  • COVID-19重症定义:诊断患者首次阳性检测后21天内进入重症监护、首次阳性检测后28天内死亡,或COVID-19被编码为根本原因的任何死亡。

研究设计与关键结果

  • 研究类型:REACT-SCOT匹配病例对照研究,纳入苏格兰截至2021年9月8日诊断的所有COVID-19病例,每例匹配10名对照。
  • 共记录5645例COVID-19重症病例,匹配50096名对照;重症病例中4495例(80%)未接种疫苗,对照中36879例(74%)未接种疫苗。
  • 已接种疫苗的COVID-19重症病例中,389例接种mRNA疫苗,759例接种ChAdOx1疫苗。
  • 疫苗接种对COVID-19重症的效力在2021年5月下降,与alpha被delta变异株取代同时发生,但该下降在随后一个月内回升。
  • 在截至2021年7月29日的最新时间窗内,两剂ChAdOx1疫苗对COVID-19重症的效力为91%(95%CI 87-94),mRNA(辉瑞或莫德纳)疫苗为92%(95%CI 88-95)。
  • ChAdOx1疫苗对COVID-19重症的效力随第二剂接种后时间下降至20周时的69%(95%CI 52-80)。
  • mRNA疫苗对COVID-19重症的效力在第二剂接种后前10周下降,此后下降更慢,至20周时为93%(95%CI 88-96)。

证据类型、等级与局限

  • 证据类型:匹配病例对照研究。
  • 局限:mRNA疫苗20周后的效力及对更新变异株的效力尚待确定。

对床旁实践的改变

  • 作者认为,结果为担心delta变异株成为优势株后疫苗对COVID-19重症的效力可能下降、或mRNA疫苗在第二剂后5-6个月内效力减弱提供了令人安心的证据。
  • 作者认为,ChAdOx1疫苗对COVID-19重症的效力在第二剂后20周明显下降。
  • 作者认为,结果支持为重症高风险人群采取额外保护措施,包括但不限于在传播率高或预计上升时接种加强针。

提炼说明

  • 本条依据论文摘要整理;摘要未涉及「处置流程与药物剂量」「红旗征与不能漏的情况」「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开

BACKGROUND: Reports have suggested that the efficacy of vaccines against COVID-19 might have fallen since the delta (B.1.617.2) SARS-CoV-2 variant replaced the alpha (B.1.1.7) variant as the predominant variant. We aimed to investigate, for the two main classes of vaccine, whether efficacy against severe COVID-19 has decreased since delta became the predominant variant and whether the efficacy of two doses of vaccine against severe COVID-19 wanes with time since second dose.

METHODS: In the REACT-SCOT case-control study, vaccine efficacy was estimated using a matched case-control design that includes all diagnosed cases of COVID-19 in Scotland up to Sept 8, 2021. For every incident case of COVID-19 in the Scottish population, ten controls matched for age rounded to the nearest year, sex, and primary care practice, and alive on the day of presentation of the case that they were matched to were selected using the Community Health Index database. To minimise ascertainment bias we prespecified the primary outcome measure to assess vaccine efficacy as severe COVID-19, defined as diagnosed patients with entry to critical care within 21 days of first positive test, death within 28 days of first positive test, or any death for which COVID-19 was coded as underlying cause. Although the data extracted for this study included cases presenting up to Sept 22, 2021, the analyses reported here are restricted to cases and controls presenting from Dec 1, 2020, to Sept 8, 2021, ensuring follow-up for at least 14 days after presentation date to allow classification of hospitalisation and (for most cases) severity based on entry to critical care or fatal outcome.

FINDINGS: During the study period, a total of 5645 severe cases of COVID-19 were recorded; these were matched to 50 096 controls. Of the severe cases, 4495 (80%) were not vaccinated, and of the controls, 36 879 (74%) were not vaccinated. Of the severe cases of COVID-19 who had been vaccinated, 389 had received an mRNA vaccine and 759 had received the ChAdOx1 vaccine. The efficacy of vaccination against severe COVID-19 decreased in May, 2021, coinciding with the replacement of the alpha SARS-CoV-2 variant by the delta variant in Scotland, but this decrease was reversed over the following month. In the most recent time window centred on July 29, 2021, the efficacy of two doses was 91% (95% CI 87-94) for the ChAdOx1 vaccine and 92% (88-95) for mRNA (Pfizer or Moderna) vaccines. The efficacy of the ChAdOx1 vaccine against severe COVID-19 declined with time since second dose to 69% (95% CI 52-80) at 20 weeks from second dose. The efficacy of mRNA vaccines declined in the first ten weeks from second dose but more slowly thereafter to 93% (88-96) at 20 weeks from second dose.

INTERPRETATION: Our results are reassuring with respect to concerns that vaccine efficacy against severe COVID-19 might have fallen since the delta variant became predominant, or that efficacy of mRNA vaccines wanes within the first 5-6 months after second dose. However, the efficacy of the ChAdOx1 vaccine against severe COVID-19 wanes substantially by 20 weeks from second dose. Efficacy of mRNA vaccines after 20 weeks and against newer variants remains to be established. Our findings support the case for additional protective measures for those at risk of severe disease, including, but not limited to, booster doses, at times when transmission rates are high or expected to rise.

来源:Lancet Respir Med,查看原文。版权归原作者所有。

参考来源

  1. McKeigue PM, McAllister DA, Hutchinson SJ, et al. Vaccine efficacy against severe COVID-19 in relation to delta variant (B.1.617.2) and time since second dose in patients in Scotland (REACT-SCOT): a case-control study. Lancet Respir Med. 2022. PMID: 35227416. doi:10.1016/S2213-2600(22)00045-5

供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。